PMID- 35170385
OWN - NLM
STAT- MEDLINE
DCOM- 20220307
LR  - 20220307
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Print)
IS  - 0886-022X (Linking)
VI  - 44
IP  - 1
DP  - 2022 Dec
TI  - MiR-122-5p promotes peritoneal fibrosis in a rat model of peritoneal dialysis by 
      targeting Smad5 to activate Wnt/beta-catenin pathway.
PG  - 191-203
LID - 10.1080/0886022X.2022.2030360 [doi]
AB  - Peritoneal fibrosis (PF) is the main reason leading to declining efficiency and 
      ultrafiltration failure of peritoneum, which restricts the application of 
      peritoneal dialysis (PD). We aimed to investigate the effects and mechanisms of 
      miR-122-5p on the PF. Sprague-Dawley (SD) rats were infused with glucose-based 
      standard PD fluid to establish PF model. HE staining was performed to evaluate 
      the extent of PF. Real-time fluorescence quantitative polymerase chain reaction 
      (RT-qPCR) and fluorescence in situ hybridization (FISH) were performed to measure 
      the expression level of miR-122-5p. Western blot was used to test the expression 
      of transforming growth factor (TGF)-beta1, platelet-derived growth factor (PDGF)-A, 
      Fibronectin 1 (FN1), extracellular matrix protein 1 (ECM1), Smad5, alpha-smooth 
      muscle actin (SMA), collagen type 1(COL-1), Vimentin, E-Cadherin, Wnt1, 
      beta-catenin, p-beta-catenin, c-Myc, c-Jun, and Cyclin D1. Immunohistochemistry (IHC) 
      staining was used to detect type I collagen alpha 1 (Col1alpha1), alpha-SMA, and 
      E-Cadherin expression. We found PF was glucose concentration-dependently enhanced 
      in peritoneum of PD rat. The PD rats showed increased miR-122-5p and decreased 
      Smad5 expression. MiR-122-5p silencing improved PF and epithelial-mesenchymal 
      transition (EMT) process in PD rats. MiR-122-5p silencing attenuated the activity 
      of the Wnt/beta-catenin signaling pathway. Importantly, dual-luciferase reporter 
      assay showed Smad5 was a target gene of miR-122-5p. Smad5 overexpression 
      significantly reversed the increases of PF and EMT progression induced by 
      miR-122-5p overexpression. Moreover, miR-122-5p mimic activated Wnt/beta-catenin 
      activity, which was blocked by Smad5 overexpression. Overall, present results 
      demonstrated that miR-122-5p overexpression showed a deterioration effect on 
      PD-related PF by targeting Smad5 to activate Wnt/beta-catenin pathway.
FAU - Liu, Yirong
AU  - Liu Y
AD  - Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.
FAU - Ma, Zhihong
AU  - Ma Z
AD  - Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.
FAU - Huang, Zhenxing
AU  - Huang Z
AD  - Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.
FAU - Zou, Dongmei
AU  - Zou D
AD  - Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.
FAU - Li, Junbin
AU  - Li J
AD  - Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.
FAU - Feng, Ping
AU  - Feng P
AD  - Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Cadherins)
RN  - 0 (MIRN122 microRNA, rat)
RN  - 0 (MicroRNAs)
RN  - 0 (Smad5 Protein)
RN  - 0 (Smad5 protein, rat)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Vimentin)
RN  - 0 (beta Catenin)
SB  - IM
MH  - Animals
MH  - Cadherins/metabolism
MH  - Epithelial-Mesenchymal Transition/*physiology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - MicroRNAs/*metabolism
MH  - Models, Animal
MH  - Peritoneal Dialysis/adverse effects
MH  - Peritoneal Fibrosis/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Smad5 Protein/*metabolism
MH  - Transforming Growth Factor beta1/metabolism
MH  - Vimentin/metabolism
MH  - Wnt Signaling Pathway
MH  - beta Catenin/metabolism
PMC - PMC8856067
OTO - NOTNLM
OT  - MiR-122-5p
OT  - Peritoneal fibrosis
OT  - Smad5
OT  - Wnt/beta-catenin
OT  - epithelial-mesenchymal transition (EMT)
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/02/17 06:00
MHDA- 2022/03/08 06:00
PMCR- 2022/02/16
CRDT- 2022/02/16 08:42
PHST- 2022/02/16 08:42 [entrez]
PHST- 2022/02/17 06:00 [pubmed]
PHST- 2022/03/08 06:00 [medline]
PHST- 2022/02/16 00:00 [pmc-release]
AID - 2030360 [pii]
AID - 10.1080/0886022X.2022.2030360 [doi]
PST - ppublish
SO  - Ren Fail. 2022 Dec;44(1):191-203. doi: 10.1080/0886022X.2022.2030360.